Trulieve Cannabis Corp. — Q1 2021 Form 10-Q
Reporting period: Three months ended March 31, 2021; unaudited. Unless stated otherwise, amounts are U.S. dollars. Financial statement amounts below are in millions.
Business context
Trulieve is a vertically integrated, multi-state cannabis operator with licenses in six states. Substantially all Q1 revenue came from medical cannabis sales in Florida; operations outside Florida and adult-use sales were not material at the time. The company reported more than 6,200 employees and approximately 2.1 million square feet of cultivation facilities across five Florida sites.
Key financial results
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue, net of discounts | $193.8 | $96.1 | +102% |
| Gross profit / gross margin | $135.3 / 70% | $73.8 / 77% | +83%; margin down 7 points |
| Operating income | $72.6 | $42.5 | +71% |
| Net income | $30.1 | $23.6 | +27% |
| Diluted earnings per share | $0.24 | $0.20 | +$0.04 |
| Adjusted EBITDA (non-GAAP) | $90.8 | $48.5 | +87% |
| Net cash from operating activities | $60.4 | $23.9 | +$36.5 |
Revenue growth reflected organic retail growth, more products and patients, and 33 additional Florida dispensaries year over year. Gross margin declined as cost of goods sold rose to 30% of revenue from 23%; management attributed the change to expansion into new markets, inventory flow-through timing, and product mix. Sales and marketing expense increased 95% to $44.6 million, general and administrative expense rose 103% to $12.7 million, and depreciation and amortization increased 148% to $5.4 million.
Income tax expense was $34.5 million, versus $17.9 million, and the effective tax rate increased to 53% from 43%. Management cited higher profit and IRC Section 280E limits on deductible expenses. Interest expense, net, was $7.9 million, compared with $5.9 million. Other expense was $0.04 million, versus $4.9 million of other income in Q1 2020, which included a warrant fair-value gain; the warrants were converted to equity in December 2020.
Cash, liquidity, and obligations
- Cash and cash equivalents were $162.5 million at March 31, 2021, up from $146.7 million at December 31, 2020. Current assets were $294.2 million and current liabilities were $100.9 million.
- Operating cash flow of $60.4 million included a $36.5 million increase in income taxes payable. Inventory and other working-capital needs also used cash.
- Investing activities used $53.4 million, primarily for property and equipment; financing activities provided $8.7 million. Capital expenditures included $49.4 million of property and equipment purchases, plus $3.7 million of purchases from construction.
- At quarter end, the company reported $6.0 million of notes payable, $12.0 million of related-party notes, and $130.0 million face value of senior secured notes due in 2024 (recorded net of issuance costs at $117.9 million). It also had $31.7 million of operating lease liabilities, $40.6 million of finance lease liabilities, and $86.4 million of construction finance liabilities.
- Management stated that existing cash was expected to cover anticipated requirements for at least 12 months from the report’s issuance. The company may seek additional debt or equity for longer-term needs; availability on acceptable terms is not assured.
Material changes, outlook, and risks
- Management attributed higher sales to retail expansion and patient and product growth, while warning that it expects sales and marketing costs to rise with new dispensaries and will continue investing in infrastructure, talent, compliance, and expansion. No numerical revenue or earnings guidance was provided.
- Q1 included ongoing Pennsylvania operations following the November 2020 acquisitions of PurePenn and Solevo Wellness. The PurePenn purchase-price allocation remained preliminary; Solevo’s allocation was finalized in 2021.
- Subsequent events included an April public offering that generated approximately $219.1 million in net proceeds; agreements for West Virginia and Pennsylvania assets; and a May 10 agreement to acquire Harvest Health & Recreation for stock consideration valued at approximately $2.1 billion based on Trulieve’s May 7 share price. The Harvest deal required shareholder, court, regulatory, and other approvals and included specified termination fees and potential loans if closing was delayed.
- Cannabis remains illegal under U.S. federal law despite state authorization. The filing warns of potential consequences including inability to carry out business plans and asset forfeiture. Section 280E also materially limits tax deductions.
- Two consolidated securities class-action cases alleging misleading statements about prior financial reporting and company prospects remained pending. The company said it considered the claims immaterial and without merit and intended to defend them.
- Management reported effective disclosure controls and no material change in internal control over financial reporting. It reported no material changes to the risk factors in its 2020 Form 10-K.
Most important facts for investors to verify
- Whether revenue growth and operating cash generation persist, particularly after accounting for the large contribution from the increase in income taxes payable.
- Whether gross margins recover as expansion, inventory flow-through, and product mix evolve, and how 280E affects cash taxes and earnings.
- The scale, timing, funding, dilution, approvals, and integration risks associated with the Harvest transaction and other announced acquisitions.
- Capital spending, construction finance obligations, lease commitments, and the company’s ability to fund expansion without unfavorable financing.
- Developments in the securities litigation and federal cannabis policy, including potential effects on licensing, assets, and operations.